Mougiakakos et al. [41] used anti-CD19 CAR T cells in a female patient with severe refractory SLE who did not respond to immunosuppressive therapy and found that the patient’s levels of double-stranded DNA autoantibodies and complement returned to normal, proteinuria improved, and the lupus disease activity index (SLEDAI) decreased from 16 to 0. This evidence concerns the gene CD19 and systemic lupus erythematosus.